Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies

Archive ouverte

Su, Yi | Flores, Shaney | Wang, Guoqiao | Hornbeck, Russ, C | Speidel, Benjamin | Joseph‐mathurin, Nelly | Vlassenko, Andrei, G | Gordon, Brian, A | Koeppe, Robert, A | Klunk, William, E | Jack, Clifford, R | Farlow, Martin, R | Salloway, Stephen | Snider, Barbara, J | Berman, Sarah, B | Roberson, Erik, D | Brosch, Jared | Jimenez‐velazques, Ivonne | van Dyck, Christopher, H | Galasko, Douglas | Yuan, Shauna, H | Jayadev, Suman | Honig, Lawrence, S | Gauthier, Serge | Hsiung, Ging‐yuek, R | Masellis, Mario | Brooks, William, S | Fulham, Michael | Clarnette, Roger | Masters, Colin, L | Wallon, David | Hannequin, Didier | Dubois, Bruno | Pariente, Jeremie | Sanchez‐valle, Raquel | Mummery, Catherine | Ringman, John, M | Bottlaender, Michel | Klein, Gregory | Milosavljevic‐ristic, Smiljana | Mcdade, Eric | Xiong, Chengjie | Morris, John, C | Bateman, Randall, J | Benzinger, Tammie, L S

Edité par CCSD ; Wiley -

International audience. Introduction: Quantitative in vivo measurement of brain amyloid burden is important for both research and clinical purposes. However, the existence of multiple imaging tracers presents challenges to the interpretation of such measurements. This study presents a direct comparison of Pittsburgh compound B-based and florbetapir-based amyloid imaging in the same participants from two independent cohorts using a crossover design. Methods: Pittsburgh compound B and florbetapir amyloid PET imaging data from three different cohorts were analyzed using previously established pipelines to obtain global amyloid burden measurements. These measurements were converted to the Centiloid scale to allow fair comparison between the two tracers. The mean and inter-individual variability of the two tracers were compared using multivariate linear models both cross-sectionally and longitudinally. Results: Global amyloid burden measured using the two tracers were strongly correlated in both cohorts. However, higher variability was observed when florbetapir was used as the imaging tracer. The variability may be partially caused by white matter signal as partial volume correction reduces the variability and improves the correlations between the two tracers. Amyloid burden measured using both tracers was found to be in association with clinical and psychometric measurements. Longitudinal comparison of the two tracers was also performed in similar but separate cohorts whose baseline amyloid load was considered elevated (i.e., amyloid positive). No significant difference was detected in the average annualized rate of change measurements made with these two tracers. Discussion: Although the amyloid burden measurements were quite similar using these two tracers as expected, difference was observable even after conversion into the Centiloid scale. Further investigation is warranted to identify optimal strategies to harmonize amyloid imaging data acquired using different tracers.

Suggestions

Du même auteur

Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease

Archive ouverte | Chen, Charles, D | CCSD

International audience. Purpose: Pittsburgh Compound-B (11C-PiB) and 18F-florbetapir are amyloid-β (Aβ) positron emission tomography (PET) radiotracers that have been used as endpoints in Alzheimer's disease (AD) cl...

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Archive ouverte | Salloway, Stephen | CCSD

International audience. Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes decades before the onset of clinical symptoms, enabling testing of interventions in the asymptomatic and ...

Multiancestry analysis of the HLA locus in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes

Archive ouverte | Le Guen, Yann | CCSD

International audience. Across multiancestry groups, we analyzed Human Leukocyte Antigen (HLA) associations in over 176,000 individuals with Parkinson’s disease (PD) and Alzheimer’s disease (AD) versus controls. We ...

Chargement des enrichissements...